Viridian Therapeutics, Inc.\DE

VRDN
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001590750

Price chart

Open-market purchases and sales by VRDN insiders, newest first.

Insider trades
Filed (ET)Trade dateInsiderTransactionSharesAvg priceValueShares afterHolding changeFiling
Aug 20, 20268:05 PM ETAug 19, 2026Tousignant JenniferChief Legal OfficerSSaleCommon Stock−14.21K$24.50−$348.19K0−100.0%SEC
May 13, 20264:31 PM ETMay 11, 2026Fairmount Healthcare Fund II L.P. and 2 othersDirector, 10% OwnerPPurchaseCommon Stock+1.18M$17.00+$20M5.09M+30.1%SEC
Jan 2, 2026Dec 31, 2025Tousignant JenniferChief Legal OfficerSSaleCommon Stock−2.27K$31.16−$70.8K0−100.0%SEC
Oct 27, 20254:30 PM ETOct 23, 2025Fairmount Healthcare Fund II L.P. and 2 othersDirector, 10% OwnerPPurchaseCommon Stock+454.55K$22.00+$10M3.91M+13.1%SEC
Sep 30, 2024Sep 27, 2024Beetham Thomas W.Chief Operating OfficerPPurchaseCommon Stock+5K$23.41+$117.05K6K+500.0%SEC

The largest institutional positions in VRDN at the end of Q2 2026.

Institutions holding VRDN in Q2 2026
InstitutionSharesValue% of portfolioChange in sharesAction
FMR LLC16,604,740$305.03M0.01%+1,225,363+8.0%Added
BlackRock, Inc.8,551,488$157.09M0.00%+720,013+9.2%Added
Bellevue Group AG6,731,909$123.67M2.60%+5,765+0.1%Added
Paradigm Biocapital Advisors LP6,723,788$123.52M2.31%+3,574,895+113.5%Added
Kynam Capital Management, LP6,453,877$118.56M6.55%+4,112,225+175.6%Added